Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy
Background Rates of Hepatitis C virus (HCV) testing and diagnosis are variable among people who use drugs (PWUD). In Puglia in 2018, of 871 subjects screened, 38% had HCV antibodies (HCVAb). Despite sustained virologic response at week 12 Sustained virologic response (SVR12) rates >95%, addiction...
Gespeichert in:
Veröffentlicht in: | United European gastroenterology journal 2021-12, Vol.9 (10), p.1109-1118 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1118 |
---|---|
container_issue | 10 |
container_start_page | 1109 |
container_title | United European gastroenterology journal |
container_volume | 9 |
creator | Mangia, Alessandra Rina, Maria Franca Canosa, Antonio Piazzolla, Valeria Squillante, Maria Maddalena Agostinacchio, Ernesto Cocomazzi, Giovanna Visaggi, Egidio Augello, Nazario Iannuzziello, Camilla Falcone, Mattia De Giorgi, Angelo Campanozzi, Fausto |
description | Background
Rates of Hepatitis C virus (HCV) testing and diagnosis are variable among people who use drugs (PWUD). In Puglia in 2018, of 871 subjects screened, 38% had HCV antibodies (HCVAb). Despite sustained virologic response at week 12 Sustained virologic response (SVR12) rates >95%, addiction centers in Italy are not allowed to prescribe direct‐acting antivirals (DAA).
Aim
To increase testing and linkage to care a dedicated program including “ad hoc” transportation and fast‐track access to care was offered to PWUD from Puglia.
Methods
Over 12 months, 1,470 individuals seen at 15 Services for Dependence (SERDs) underwent screening. For HCVAb positive, a fast‐track evaluation was offered at our Hepatology Unit. Patients were subsequently taken to their pharmacists to receive the prescribed DAA regimen. Treatment and adherence were supervised by SERDs physicians, SVR12 assessed at our unit. The scalability of the process was based on both, number of patients screened in our region in 2018, and number of PWUD diagnosed and treated at our center during 2018–2019.
Results
Of 1,470 individuals screened, 634 (43.1%) tested HCVAb positive. Overall, 231 were RNA positive, 54% of whom on opioid agonist therapy (OAT) and 32% with cirrhosis. Median interval between RNA assessment and treatment start was 22 days (0–300). Patients received 12‐week sofosbuvir/velpatasvir regimen without Ribavirin; in 220 patients who completed treatment, SVR12 was 98.6%. Among GT3, SVR12 was 98%. No re‐infection was observed. Improvements in screening, and linkage to care were registered.
Conclusions
A PWUD‐tailored service led to HCV care cascade improvement and high SVR12 rates. Despite history of drug addiction, social instability and logistic barriers, micro‐elimination programs providing dedicated care are key drivers of success. |
doi_str_mv | 10.1002/ueg2.12156 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8672087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3090897998</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4486-74574117a3faa24a2fa0969ee71be6918a8e1f8ffdad286ddcedff72345335d53</originalsourceid><addsrcrecordid>eNp9kcFu1DAURSMEolXphg9AltggxBTbcRxng4RGpR2pEpt2bb3GzxmXxA520mp2_YRu-EG-BA9TRsCi3jxL9-i--3SL4jWjJ4xS_nHGjp8wzir5rDjktKILKZh4vv9TeVAcp3RD81NKcC5eFgelkE3dMHZY_Fj5NiIkNOQcR5jc5BJZklsX50RSltA7330gxkHnQ8oieEN6579Bh2QKpIWIJMKEWRmC78iIYeyR3K0DmRMSE-cukWkdw9ytCZDtDvTTz_uHNg-MefEYQxdhIDaGgawm6DevihcW-oTHj_OouPpyerk8X1x8PVstP18sWiGUXNSiqgVjNZQWgAvgFmgjG8SaXaNsmAKFzCprDRiupDEtGmtrXoqqLCtTlUfFp53vOF8PaLaJIvR6jG6AuNEBnP5X8W6tu3Crlaw5VXU2ePdoEMP3GdOkB5da7HvwGOakeaWkqFhVsoy-_Q-9CXP0-Txd0oaqXEijMvV-R7UxpBTR7sMwqreF623h-nfhGX7zd_w9-qfeDLAdcOd63Dxhpa9Oz_jO9Bf_O7mD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090897998</pqid></control><display><type>article</type><title>Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy</title><source>Wiley-Blackwell Journals</source><source>PubMed (Medline)</source><source>Wiley Online Library website</source><source>MEDLINE</source><creator>Mangia, Alessandra ; Rina, Maria Franca ; Canosa, Antonio ; Piazzolla, Valeria ; Squillante, Maria Maddalena ; Agostinacchio, Ernesto ; Cocomazzi, Giovanna ; Visaggi, Egidio ; Augello, Nazario ; Iannuzziello, Camilla ; Falcone, Mattia ; De Giorgi, Angelo ; Campanozzi, Fausto</creator><creatorcontrib>Mangia, Alessandra ; Rina, Maria Franca ; Canosa, Antonio ; Piazzolla, Valeria ; Squillante, Maria Maddalena ; Agostinacchio, Ernesto ; Cocomazzi, Giovanna ; Visaggi, Egidio ; Augello, Nazario ; Iannuzziello, Camilla ; Falcone, Mattia ; De Giorgi, Angelo ; Campanozzi, Fausto</creatorcontrib><description>Background
Rates of Hepatitis C virus (HCV) testing and diagnosis are variable among people who use drugs (PWUD). In Puglia in 2018, of 871 subjects screened, 38% had HCV antibodies (HCVAb). Despite sustained virologic response at week 12 Sustained virologic response (SVR12) rates >95%, addiction centers in Italy are not allowed to prescribe direct‐acting antivirals (DAA).
Aim
To increase testing and linkage to care a dedicated program including “ad hoc” transportation and fast‐track access to care was offered to PWUD from Puglia.
Methods
Over 12 months, 1,470 individuals seen at 15 Services for Dependence (SERDs) underwent screening. For HCVAb positive, a fast‐track evaluation was offered at our Hepatology Unit. Patients were subsequently taken to their pharmacists to receive the prescribed DAA regimen. Treatment and adherence were supervised by SERDs physicians, SVR12 assessed at our unit. The scalability of the process was based on both, number of patients screened in our region in 2018, and number of PWUD diagnosed and treated at our center during 2018–2019.
Results
Of 1,470 individuals screened, 634 (43.1%) tested HCVAb positive. Overall, 231 were RNA positive, 54% of whom on opioid agonist therapy (OAT) and 32% with cirrhosis. Median interval between RNA assessment and treatment start was 22 days (0–300). Patients received 12‐week sofosbuvir/velpatasvir regimen without Ribavirin; in 220 patients who completed treatment, SVR12 was 98.6%. Among GT3, SVR12 was 98%. No re‐infection was observed. Improvements in screening, and linkage to care were registered.
Conclusions
A PWUD‐tailored service led to HCV care cascade improvement and high SVR12 rates. Despite history of drug addiction, social instability and logistic barriers, micro‐elimination programs providing dedicated care are key drivers of success.</description><identifier>ISSN: 2050-6406</identifier><identifier>ISSN: 2050-6414</identifier><identifier>EISSN: 2050-6414</identifier><identifier>DOI: 10.1002/ueg2.12156</identifier><identifier>PMID: 34697911</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Antiviral Agents - therapeutic use ; antiviral treatment ; cirrhosis ; COVID-19 ; Disease transmission ; Drug use ; Drug Users ; Female ; HCV ; Health care access ; Health Services Accessibility - organization & administration ; Hepatitis Antibodies - blood ; Hepatitis C ; Hepatitis C, Chronic - diagnosis ; Hepatitis C, Chronic - drug therapy ; Hepatobiliary ; Humans ; Infections ; Italy ; linkage to care ; Male ; Mass Screening ; micro‐elimination ; Middle Aged ; Original ; Pandemics ; Patients ; people who use drugs ; PWUD ; screening ; sofosbuvir/velpatasvir ; Sustained Virologic Response ; Transportation services ; Viruses ; Young Adult</subject><ispartof>United European gastroenterology journal, 2021-12, Vol.9 (10), p.1109-1118</ispartof><rights>2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4486-74574117a3faa24a2fa0969ee71be6918a8e1f8ffdad286ddcedff72345335d53</citedby><cites>FETCH-LOGICAL-c4486-74574117a3faa24a2fa0969ee71be6918a8e1f8ffdad286ddcedff72345335d53</cites><orcidid>0000-0002-2600-3555</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672087/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672087/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34697911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mangia, Alessandra</creatorcontrib><creatorcontrib>Rina, Maria Franca</creatorcontrib><creatorcontrib>Canosa, Antonio</creatorcontrib><creatorcontrib>Piazzolla, Valeria</creatorcontrib><creatorcontrib>Squillante, Maria Maddalena</creatorcontrib><creatorcontrib>Agostinacchio, Ernesto</creatorcontrib><creatorcontrib>Cocomazzi, Giovanna</creatorcontrib><creatorcontrib>Visaggi, Egidio</creatorcontrib><creatorcontrib>Augello, Nazario</creatorcontrib><creatorcontrib>Iannuzziello, Camilla</creatorcontrib><creatorcontrib>Falcone, Mattia</creatorcontrib><creatorcontrib>De Giorgi, Angelo</creatorcontrib><creatorcontrib>Campanozzi, Fausto</creatorcontrib><title>Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy</title><title>United European gastroenterology journal</title><addtitle>United European Gastroenterol J</addtitle><description>Background
Rates of Hepatitis C virus (HCV) testing and diagnosis are variable among people who use drugs (PWUD). In Puglia in 2018, of 871 subjects screened, 38% had HCV antibodies (HCVAb). Despite sustained virologic response at week 12 Sustained virologic response (SVR12) rates >95%, addiction centers in Italy are not allowed to prescribe direct‐acting antivirals (DAA).
Aim
To increase testing and linkage to care a dedicated program including “ad hoc” transportation and fast‐track access to care was offered to PWUD from Puglia.
Methods
Over 12 months, 1,470 individuals seen at 15 Services for Dependence (SERDs) underwent screening. For HCVAb positive, a fast‐track evaluation was offered at our Hepatology Unit. Patients were subsequently taken to their pharmacists to receive the prescribed DAA regimen. Treatment and adherence were supervised by SERDs physicians, SVR12 assessed at our unit. The scalability of the process was based on both, number of patients screened in our region in 2018, and number of PWUD diagnosed and treated at our center during 2018–2019.
Results
Of 1,470 individuals screened, 634 (43.1%) tested HCVAb positive. Overall, 231 were RNA positive, 54% of whom on opioid agonist therapy (OAT) and 32% with cirrhosis. Median interval between RNA assessment and treatment start was 22 days (0–300). Patients received 12‐week sofosbuvir/velpatasvir regimen without Ribavirin; in 220 patients who completed treatment, SVR12 was 98.6%. Among GT3, SVR12 was 98%. No re‐infection was observed. Improvements in screening, and linkage to care were registered.
Conclusions
A PWUD‐tailored service led to HCV care cascade improvement and high SVR12 rates. Despite history of drug addiction, social instability and logistic barriers, micro‐elimination programs providing dedicated care are key drivers of success.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - therapeutic use</subject><subject>antiviral treatment</subject><subject>cirrhosis</subject><subject>COVID-19</subject><subject>Disease transmission</subject><subject>Drug use</subject><subject>Drug Users</subject><subject>Female</subject><subject>HCV</subject><subject>Health care access</subject><subject>Health Services Accessibility - organization & administration</subject><subject>Hepatitis Antibodies - blood</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - diagnosis</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatobiliary</subject><subject>Humans</subject><subject>Infections</subject><subject>Italy</subject><subject>linkage to care</subject><subject>Male</subject><subject>Mass Screening</subject><subject>micro‐elimination</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Pandemics</subject><subject>Patients</subject><subject>people who use drugs</subject><subject>PWUD</subject><subject>screening</subject><subject>sofosbuvir/velpatasvir</subject><subject>Sustained Virologic Response</subject><subject>Transportation services</subject><subject>Viruses</subject><subject>Young Adult</subject><issn>2050-6406</issn><issn>2050-6414</issn><issn>2050-6414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kcFu1DAURSMEolXphg9AltggxBTbcRxng4RGpR2pEpt2bb3GzxmXxA520mp2_YRu-EG-BA9TRsCi3jxL9-i--3SL4jWjJ4xS_nHGjp8wzir5rDjktKILKZh4vv9TeVAcp3RD81NKcC5eFgelkE3dMHZY_Fj5NiIkNOQcR5jc5BJZklsX50RSltA7330gxkHnQ8oieEN6579Bh2QKpIWIJMKEWRmC78iIYeyR3K0DmRMSE-cukWkdw9ytCZDtDvTTz_uHNg-MefEYQxdhIDaGgawm6DevihcW-oTHj_OouPpyerk8X1x8PVstP18sWiGUXNSiqgVjNZQWgAvgFmgjG8SaXaNsmAKFzCprDRiupDEtGmtrXoqqLCtTlUfFp53vOF8PaLaJIvR6jG6AuNEBnP5X8W6tu3Crlaw5VXU2ePdoEMP3GdOkB5da7HvwGOakeaWkqFhVsoy-_Q-9CXP0-Txd0oaqXEijMvV-R7UxpBTR7sMwqreF623h-nfhGX7zd_w9-qfeDLAdcOd63Dxhpa9Oz_jO9Bf_O7mD</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Mangia, Alessandra</creator><creator>Rina, Maria Franca</creator><creator>Canosa, Antonio</creator><creator>Piazzolla, Valeria</creator><creator>Squillante, Maria Maddalena</creator><creator>Agostinacchio, Ernesto</creator><creator>Cocomazzi, Giovanna</creator><creator>Visaggi, Egidio</creator><creator>Augello, Nazario</creator><creator>Iannuzziello, Camilla</creator><creator>Falcone, Mattia</creator><creator>De Giorgi, Angelo</creator><creator>Campanozzi, Fausto</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2600-3555</orcidid></search><sort><creationdate>202112</creationdate><title>Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy</title><author>Mangia, Alessandra ; Rina, Maria Franca ; Canosa, Antonio ; Piazzolla, Valeria ; Squillante, Maria Maddalena ; Agostinacchio, Ernesto ; Cocomazzi, Giovanna ; Visaggi, Egidio ; Augello, Nazario ; Iannuzziello, Camilla ; Falcone, Mattia ; De Giorgi, Angelo ; Campanozzi, Fausto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4486-74574117a3faa24a2fa0969ee71be6918a8e1f8ffdad286ddcedff72345335d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - therapeutic use</topic><topic>antiviral treatment</topic><topic>cirrhosis</topic><topic>COVID-19</topic><topic>Disease transmission</topic><topic>Drug use</topic><topic>Drug Users</topic><topic>Female</topic><topic>HCV</topic><topic>Health care access</topic><topic>Health Services Accessibility - organization & administration</topic><topic>Hepatitis Antibodies - blood</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - diagnosis</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatobiliary</topic><topic>Humans</topic><topic>Infections</topic><topic>Italy</topic><topic>linkage to care</topic><topic>Male</topic><topic>Mass Screening</topic><topic>micro‐elimination</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Pandemics</topic><topic>Patients</topic><topic>people who use drugs</topic><topic>PWUD</topic><topic>screening</topic><topic>sofosbuvir/velpatasvir</topic><topic>Sustained Virologic Response</topic><topic>Transportation services</topic><topic>Viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mangia, Alessandra</creatorcontrib><creatorcontrib>Rina, Maria Franca</creatorcontrib><creatorcontrib>Canosa, Antonio</creatorcontrib><creatorcontrib>Piazzolla, Valeria</creatorcontrib><creatorcontrib>Squillante, Maria Maddalena</creatorcontrib><creatorcontrib>Agostinacchio, Ernesto</creatorcontrib><creatorcontrib>Cocomazzi, Giovanna</creatorcontrib><creatorcontrib>Visaggi, Egidio</creatorcontrib><creatorcontrib>Augello, Nazario</creatorcontrib><creatorcontrib>Iannuzziello, Camilla</creatorcontrib><creatorcontrib>Falcone, Mattia</creatorcontrib><creatorcontrib>De Giorgi, Angelo</creatorcontrib><creatorcontrib>Campanozzi, Fausto</creatorcontrib><collection>Wiley Online Library website</collection><collection>Wiley Online Library Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>United European gastroenterology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mangia, Alessandra</au><au>Rina, Maria Franca</au><au>Canosa, Antonio</au><au>Piazzolla, Valeria</au><au>Squillante, Maria Maddalena</au><au>Agostinacchio, Ernesto</au><au>Cocomazzi, Giovanna</au><au>Visaggi, Egidio</au><au>Augello, Nazario</au><au>Iannuzziello, Camilla</au><au>Falcone, Mattia</au><au>De Giorgi, Angelo</au><au>Campanozzi, Fausto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy</atitle><jtitle>United European gastroenterology journal</jtitle><addtitle>United European Gastroenterol J</addtitle><date>2021-12</date><risdate>2021</risdate><volume>9</volume><issue>10</issue><spage>1109</spage><epage>1118</epage><pages>1109-1118</pages><issn>2050-6406</issn><issn>2050-6414</issn><eissn>2050-6414</eissn><abstract>Background
Rates of Hepatitis C virus (HCV) testing and diagnosis are variable among people who use drugs (PWUD). In Puglia in 2018, of 871 subjects screened, 38% had HCV antibodies (HCVAb). Despite sustained virologic response at week 12 Sustained virologic response (SVR12) rates >95%, addiction centers in Italy are not allowed to prescribe direct‐acting antivirals (DAA).
Aim
To increase testing and linkage to care a dedicated program including “ad hoc” transportation and fast‐track access to care was offered to PWUD from Puglia.
Methods
Over 12 months, 1,470 individuals seen at 15 Services for Dependence (SERDs) underwent screening. For HCVAb positive, a fast‐track evaluation was offered at our Hepatology Unit. Patients were subsequently taken to their pharmacists to receive the prescribed DAA regimen. Treatment and adherence were supervised by SERDs physicians, SVR12 assessed at our unit. The scalability of the process was based on both, number of patients screened in our region in 2018, and number of PWUD diagnosed and treated at our center during 2018–2019.
Results
Of 1,470 individuals screened, 634 (43.1%) tested HCVAb positive. Overall, 231 were RNA positive, 54% of whom on opioid agonist therapy (OAT) and 32% with cirrhosis. Median interval between RNA assessment and treatment start was 22 days (0–300). Patients received 12‐week sofosbuvir/velpatasvir regimen without Ribavirin; in 220 patients who completed treatment, SVR12 was 98.6%. Among GT3, SVR12 was 98%. No re‐infection was observed. Improvements in screening, and linkage to care were registered.
Conclusions
A PWUD‐tailored service led to HCV care cascade improvement and high SVR12 rates. Despite history of drug addiction, social instability and logistic barriers, micro‐elimination programs providing dedicated care are key drivers of success.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>34697911</pmid><doi>10.1002/ueg2.12156</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2600-3555</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2050-6406 |
ispartof | United European gastroenterology journal, 2021-12, Vol.9 (10), p.1109-1118 |
issn | 2050-6406 2050-6414 2050-6414 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8672087 |
source | Wiley-Blackwell Journals; PubMed (Medline); Wiley Online Library website; MEDLINE |
subjects | Adult Aged Antiviral Agents - therapeutic use antiviral treatment cirrhosis COVID-19 Disease transmission Drug use Drug Users Female HCV Health care access Health Services Accessibility - organization & administration Hepatitis Antibodies - blood Hepatitis C Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy Hepatobiliary Humans Infections Italy linkage to care Male Mass Screening micro‐elimination Middle Aged Original Pandemics Patients people who use drugs PWUD screening sofosbuvir/velpatasvir Sustained Virologic Response Transportation services Viruses Young Adult |
title | Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A45%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20Hepatitis%20C%20virus%20screening,%20diagnosis%20and%20linkage%20to%20care%20rates%20among%20people%20who%20use%20drugs%20through%20a%20patient%E2%80%90centered%20program%20from%20Italy&rft.jtitle=United%20European%20gastroenterology%20journal&rft.au=Mangia,%20Alessandra&rft.date=2021-12&rft.volume=9&rft.issue=10&rft.spage=1109&rft.epage=1118&rft.pages=1109-1118&rft.issn=2050-6406&rft.eissn=2050-6414&rft_id=info:doi/10.1002/ueg2.12156&rft_dat=%3Cproquest_pubme%3E3090897998%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3090897998&rft_id=info:pmid/34697911&rfr_iscdi=true |